

PRECLINICAL TESTING

PHASE 1

PHASE 2

PHASE 3

BLA/NDMA/MAA

COMMERCIALIZATION

Seven Commercial Products

Palynziq™
(pegvaliase-pqpz) Injection

Brineura™
(cerliponase alfa)

Naglazyme®
(GALSULFASE)

KUVAN®
(sapropterin dihydrochloride) Tablets

ALDURAZYME®
(LARNIDASE)

VIMIZIM®
(elosulfase alfa)

FIRDAPSE™
amifampridine

Vosoritide for Achondroplasia

Valoctocogene roxaparvovec for Hemophilia A (under AA pathway)

Tralesinidase Alfa for MPS IIIB, or Sanfilippo Type B

BMN 307 Gene Therapy for PKU

BMN 290 for Friedreich's Ataxia

Corporate Overview

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of several commercial products and multiple clinical and pre-clinical product candidates for the treatment of various diseases.

General Company Information

- Founded in 1997
- IPO in 1999, NASDAQ ticker BMRN
- More than 2,800 employees worldwide
- Global sales in 76 markets worldwide

BioMarin Facilities

- Headquarters in San Rafael, California
- Manufacturing in Novato, California and Shanbally, Ireland
- Regional offices in Dublin, London, Hong Kong, and Sao Paulo

(information as of February 12, 2019)

BioMarin at a Glance


- ~400% Increase in revenues from 2008 to 2018
- Made the *Forbes* Most Innovative Companies list the past 4 years in a row
- 20th year of scientific innovation
- 7 FDA and EMA approved products
- 2 products currently in late-stage development
- 1st ERT therapy into the CNS via ICV delivery
- 5 years on average from IND to approval for all marketed products
- 178,372,202 shares outstanding

Financial Outlook

Actual and Estimated Revenue 2005-2019

- Palynziq
- Brineura
- Vimizim
- Naglazyme
- Kuvan
- Aldurazyme + Other

(Revenues in millions)



Full Year 2019 Revenue Guidance

(\$ in millions)

Item	Provided 2/21/19
Total BioMarin Revenues	\$1,680 to \$1,750
Vimizim	\$530 to \$570
Kuvan	\$420 to \$460
Naglazyme	\$350 to \$380
Palynziq	\$70 to \$100
Brineura	\$55 to \$75

Selected Income Statement Guidance

(\$ in millions, except percentages)

Item	Provided 2/21/19
Cost of Sales(% of Total Rev.)	20% to 21%
R&D Expense	\$740 to \$780
SG&A Expense	\$650 to \$690
Non-GAAP Net Income	\$130 to \$170
GAAP Net Loss	\$(45) to \$(85)


Executive Management

Jean-Jacques Bienaimé – Chairman and Chief Executive Officer
 Hank Fuchs, M.D. – President, Worldwide Research and Development
 Robert A. Baffi, Ph.D. – Executive Vice President, Technical Operations
 Dan Spiegelman – Executive Vice President and Chief Financial Officer
 Jeff Ajer – Executive Vice President and Chief Commercial Officer

Board of Directors

Jean-Jacques Bienaimé V. Bryan Lawlis, Ph.D.
 Willard H. Dere, M.D. Alan J. Lewis, Ph.D.
 Michael Grey Randy Meier
 Elaine J. Heron, Ph.D. David Pyott
 Robert Hombach Dennis J. Slamon, M.D., Ph.D.

BioMarin Global Footprint



- ★ Headquarters
- Regional Office
- Manufacturing

(Information as of 1Q19)